Similarly, the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide reduces PCSK9 levels in an HNF1α-dependent manner, ameliorating lipid metabolism disorders in type 2 diabetes(146). This evidence concerns the gene GCG and type 2 diabetes mellitus.